Article

Liver Status Assessment by Spectrally and Time Resolved IR Detection of Drug Induced Breath Gas Changes

Tom Rubin ^{1,2}, Theodore von Haimberger ¹, Alexander Helmke ¹, Johan Lock ^{2,3}, Martin Stockmann ² and Karsten Heyne ^{1,*}

¹ Department of Experimental Physics, Free University Berlin, Arnimallee 14, 14195 Berlin, Germany; mores.rubin@googlemail.com (T.R.); haimberg@physik.fu-berlin.de (T.v.H.); alexander.helmke@humedics.de (A.H.)

² Department of General, Visceral and Transplantation Surgery, Charité-Universitätsmedizin, 13353 Berlin, Germany; Lock_J@ukw.de (J.L.); martin.stockmann@charite.de (M.S.)

³ Department of General, Visceral, Vascular and Pediatric Surgery, University Hospital of Wuerzburg, Josef-Schneider-Straße 2, 97080 Wuerzburg, Germany

* Correspondence: Karsten.heyne@fu-berlin.de; Tel.: +49-30-8385-6107

Received: 31 March 2016; Accepted: 30 April 2016; Published: 20 May 2016

Abstract: The actual metabolic capacity of the liver is crucial for disease identification, liver therapy, and liver tumor resection. By combining induced drug metabolism and high sensitivity IR spectroscopy of exhaled air, we provide a method for quantitative liver assessment at bedside within 20 to 60 min. Fast administration of ¹³C-labelled methacetin induces a fast response of liver metabolism and is tracked in real-time by the increase of ¹³CO₂ in exhaled air. The ¹³CO₂ concentration increase in exhaled air allows the determination of the metabolic liver capacity (LiMAx-test). Fluctuations in CO₂ concentration, pressure and temperature are minimized by special gas handling, and tracking of several spectrally resolved CO₂ absorption bands with a quantum cascade laser. Absorption measurement of different ¹²CO₂ and ¹³CO₂ rotation-vibration transitions in the same time window allows for multiple referencing and reduction of systematic errors. This FLIP (Fast liver investigation package) setup is being successfully used to plan operations and determine the liver status of patients.

Keywords: QCL; liver status; ¹³CO₂; breath test; LiMAx; rotation-vibration spectroscopy

1. Introduction

Exhaled air provides information on the concentration of volatile organic compounds, oxygen, CO₂, and other gases (e.g., HCN) in the blood. These compounds can reflect metabolic processes and storage of gases inhaled before [1]. One of the main compounds in exhaled air is CO₂. Concentration changes of CO₂ in exhaled air can result from the metabolism of nutrients and from changes in metabolism. Therefore, it is a difficult task to assign concentration changes to a specific metabolic process. The LiMAx test (liver maximal capacity) describes a procedure to assign ¹³CO₂ concentration changes in exhaled breath to a single metabolic process in liver cells. The most important point is fast intravenous (IV) administration of the drug ¹³C-methacetin—much faster than the redistribution processes within the human body. The drug ¹³C-methacetin is solely metabolized by the enzyme cytochrome P450 1A2 (CYP450 1A2) into ¹³CO₂ and paracetamol. Since CYP450 1A2 exists only in liver cells, the additionally generated ¹³CO₂ reflects the metabolism of the liver. Under normal conditions, the proportion of exhaled ¹³CO₂ in the breath volume amounts to 1% of the exhaled ¹²CO₂ due to its natural abundance, and is about 0.02%–0.05% of the exhaled volume. The ratio, R, of ¹³CO₂ to ¹²CO₂ is expected to be constant and is measured to identify alterations due

to additional metabolic processes of administered ^{13}C enriched substrates [2]. Typically, this ratio (R) is constant with only small and slow variations of less than $\pm 1\%$ reflecting the natural abundance of ^{13}C in nutrients [3]. Upon administration of ^{13}C -methacetin, followed by metabolism into $^{13}\text{CO}_2$, R increases on a time scale of the metabolic process. The change of R as a function of time is plotted as DOB (Delta over baseline) kinetic in per-mil.

The LiMAx test uses the maximum of the DOB kinetics to calculate the LiMAx value using Equation (1) [4]:

$$\text{LiMAx} = \frac{(\text{DOB}(t_{\max}) - \text{DOB}(t_0))R_{\text{PDB}}PM}{m} \quad (1)$$

Here, $\text{DOB}(t_{\max})$ is the maximum of the DOB kinetics, and $\text{DOB}(t_0)$ the constant value before ^{13}C -methacetin administration. The amplitude of the DOB kinetics is directly proportional to the LiMAx value. The natural abundance of ^{13}C is taken into account by $R_{\text{PDB}} = 0.0112375$ [5], P is the calculated average molar CO_2 production of the patient [6,7], m is the body weight of the patient, and M is the molar mass of methacetin. The administered dose of ^{13}C -methacetin was 2 mg/kg body weight. The LiMAx value provides a personalized measure of a metabolic liver parameter. This value encompasses an average property of the metabolic capacity of the liver, since CYP450 1A2 is evenly distributed in the liver cells. Specific information on metabolic processes in liver subsections or on circulatory problems in the liver are not included. Nevertheless, information on the metabolic liver status is essential for operations, in particular, liver operations. Included in the clinical routine, the LiMAx test allows for a reduction in the mortality rate after liver resections by more than 70% [8,9].

For an individual patient, the accuracy of the LiMAx value is dominated by the precision of the detection of the DOB kinetics. Here, we describe the FLIP device (fast liver investigation package) developed for precise measurement of the DOB kinetics at bedside.

2. Materials and Methods

2.1. Handling of Breath Gas

A single exhaled breath contains a mixture of gases, changing in concentration and composition, during exhalation. Typically, the CO_2 concentration is maximal at the final part of the exhaled air, since this volume stays the longest in the lung and is minimal at the beginning due to the non-enrichment of the inhaled air [10]. In Figure 1, the CO_2 concentration is depicted for several breaths as a function of time (black line). The concentration was measured by spectrally broad integrated absorption of rotation-vibration transitions of $^{13}\text{CO}_2$ and $^{12}\text{CO}_2$ [11]. The setup we used for all measurements is depicted in Figure 2. The prototype of this FLIP setup was described earlier [10]. Here, we focus on differences made to develop the FLIP device for medical certification and daily application in a hospital. As depicted in Figure 2, the complete breath is exhaled into the FLIP device. The respiration of the person transports the gas into and through the sample chamber. Every new breath presses the previous breath out of the FLIP device. No valves or pumps are needed. While the whole breath flows through the FLIP, absorption measurements were performed in the sample chamber.

In Figure 1, the detected CO_2 concentration and the gas flow is presented for two situations. First, the complete setup is used, second, the measurements were performed without the mixing chamber depicted in Figure 2. Without the mixing chamber, the black line reflects the concentration change in the sample chamber, and, the blue line, the gas flow. The decrease of the concentration reflects the first part of the breath with low a CO_2 concentration, followed by the second part of the breath with an increasing CO_2 concentration. Between the breaths (blue line), the gas concentration stays constant in the sample chamber, as indicated by the plateaus (black line). Thus, diffusion of CO_2 out of the chamber is slow and negligible. The gas flow was measured by a spirometer (Go-Link)—with home built calibration—indicating the breath cycle and movement of the gas [11]. Combination of the gas flow, the sample chamber size, and the concentration allows determination of the absolute exhaled CO_2 amount as a function of time. The concentration of the exhaled CO_2 depicted in Figure 1

shows rather constant CO_2 concentrations in the later part of exhalation, with relative changes of about 0.6%. These small alterations are on the same order as expected relative to the changes of $^{13}\text{CO}_2$ exhalation after ^{13}C -methacetin administration in the LiMAX test. It has been long known that alveolar gas exchange is dependent on ventilation, pulmonary perfusion, and the blood:air partition coefficient, and that breath samples are not well reproducible [12]. Thus, the $^{12}\text{CO}_2$ and $^{13}\text{CO}_2$ concentrations have to be measured at the same or on a time scale much faster than the breath cycle. In the beginning of exhalation, the CO_2 concentration is low since the inhaled air is poorly mixed with gas from the alveolar region. With an increasing fraction of alveolar air, the concentration rises strongly until the contribution by the air in the airways is negligible. Hence, the concentration varies strongly during the complete breath cycle, making high demands on the dynamic range of the measurement device. Moreover, the temperature of the exhaled gas changes with increasing residence time in the lung, and the pressure of the exhaled air also varies during exhalation. In order to balance the inhomogeneity of the concentration, and temperature we used a mixing chamber of an average breath volume of ~ 0.5 L. The mixing chamber is depicted in Figure 2 and consists of a part with a syntex membrane reducing the water content in the breath. In the second part, the gas is mixed by several continuations at three different positions along the gas stream, as detailed elsewhere [13]. As presented in Figure 1 (green line), the mixing chamber smooths the CO_2 concentration considerably, enabling measurements with a high signal to noise ratio for successive breaths. In the whole setup, the cross section is constant to ensure a laminar gas flow. Furthermore, the setup always has an open gas exit, as depicted in Figure 2, preventing pressure increase in the device.

Figure 1. CO_2 concentrations of exhaled breaths (left scale) and the associated gas flow induced by the breathing cycle (right scale): Successive exhaled breaths measured in the FLIP (fast liver investigation package) device without mixing chamber: CO_2 concentration (black line) and gas flow (blue line), concentration changes are mainly due to alterations of the alveolar air proportion; successive exhaled breaths measured in the FLIP device with mixing chamber: CO_2 concentration (green line) and gas flow (dark yellow line).

Figure 2. Schematic setup of a FLIP device with mixing chamber, sample chamber with sapphire windows, detectors D_1 and D_2 , quantum cascade laser (QCL), lenses L , and flow meter. The exhaled breath is pushed through the setup by respiration (see arrows). Note, the cross section of the whole setup is kept constant to ensure a laminar flow of the gas. The sample chamber, framed by the two sapphire windows W_1 and W_2 , has a length of 10 cm, and a cross sectional area of 5 cm^2 .

2.2. Spectral Tuning

We decided to use infrared (IR) absorption spectroscopy to measure the concentration of $^{12}\text{CO}_2$ and $^{13}\text{CO}_2$ in exhaled air, because this method is very fast and achieves a high sensitivity and resolution. The high sensitivity is essential, because the dosage of methacetin should be as low as possible. As is visible in Figure 3, the high spectral resolution is needed for exact separation of $^{12}\text{CO}_2$ and $^{13}\text{CO}_2$ contributions in the breath without any cross-talk. Comparing the slow exhalation time of a breath on a time scale of seconds with the fast measurement of a spectrum presented in Figure 3 on a time scale of ms, it is evident that the fast method allows for multiple averages on a time scale of almost constant breath concentration. Rotation-vibration transitions of $^{12}\text{CO}_2$ and $^{13}\text{CO}_2$ absorption with a relative high extinction coefficient in the spectral range around 2200 cm^{-1} to 2400 cm^{-1} [10].

Figure 3. Selected spectral window and simulated positions of $^{12}\text{CO}_2$ (black lines) and $^{13}\text{CO}_2$ (blue lines) absorption. Left scale: Absorption in cm^2 per molecule as a function of wavenumber. Positions and absorption/extinction coefficients were taken from the HITRAN (High Resolution Transmission) database for a simulated linewidth of 0.19 cm^{-1} (FWHM) Right scale: Detected absorption in optical density OD (without units) according to Lambert Beer law (green circles and lines, right scale).

A spectral region where absorptions of $^{12}\text{CO}_2$ and $^{13}\text{CO}_2$ in the exhaled breath have the same order of magnitude is depicted in Figure 3. An optimal light source to spectrally resolve the absorption lines in this spectral range is a quantum cascade laser (QCL) [14–16]. Our pulsed QCL from Alpes Lasers with a driver unit from neoplas control GmbH is tunable in a spectral window of about 2 cm^{-1} width within 10 ms by a voltage ramp (sweep) and a laser repetition rate of 100 kHz. Another 10 ms was used to let the QCL temperature equilibrate. Thus, we collect spectra with 50 Hz. Our home built electronics enables us to detect up to 1000 spectral positions per sweep. The exact frequency positions are calibrated by the known absorption frequencies, and the linearity by measurements with a Ge etalon (MG optical solutions GmbH). The spectral position of the QCL is adjusted by a temperature controller to 2298 cm^{-1} (neoplas control GmbH).

2.3. Spectral Readjustment

With this setup we are able to perform repetitive measurements of absorption spectra as depicted in Figure 3. Nevertheless, the temperature controller showed some small fluctuations resulting in clearly visible spectral shifts in the absorption spectrum. Therefore, we use the positions of the absorption peaks to readjust the temperature controller by an automatic feedback loop. A robust method to identify spectral shifts is presented in Figure 4. Symmetric to the maximum of each absorption peak, we integrated areas on the high energy (left) and low energy (right) side of the peak. A change of the ratio of both areas were used as an indication of a spectral peak shift. The spectral shift is corrected by readjustment of the temperature controller. This procedure results in absorption spectra without detectable spectral shifts, *i.e.*, with spectral shifts smaller than $\sim 0.01\text{ cm}^{-1}$. This enabled us to average multiple spectra to increase the signal to noise ratio. This procedure was used during measurements of DOB kinetics is shown in Figure 5.

Figure 4. Absorption spectrum measured by the voltage ramp [17]. The peak positions at channel 18 (blue line) and channel 36 (red line) reflect $^{12}\text{CO}_2$ and $^{13}\text{CO}_2$ absorption lines, respectively. This method can be used without calibration and conversion of channels to wavenumbers. Every datapoint defines a channel. Integrated areas, symmetric to the left and right of the absorption maxima of both peaks are highlighted (crosshatched areas). The ratio of crosshatched areas for each peak are used to identify peak position shifts. Presented absorption lines are crosshatched in Figure 2.

2.4. Setup

The setup is depicted in Figure 2. The exhaled air flows through the mixing chamber (blue box) into the sample chamber (black box) where the concentrations are measured continuously. The gas flow is measured behind the sample chamber with a spirometer (magenta box) before the gas left the setup. We use a special face mask with valves separating inhaled and exhaled air, allowing only exhalation into the setup. Data acquisition is performed at 100 kHz with a laser repetition rate of

100 kHz, and 16 bit resolution (A/D converter). As presented in Figure 2, the laser pulse of several nanoseconds is collimated and split by the entrance window of the sample chamber (W_2 , orange line) into a probe and reference beam. The reference beam is directed and focused on a MCT (photovoltaic mercury cadmium telluride, from Laser components) detector D_2 to measure the intensity signal I_2 without breath gas absorption. The probe beam passes through the sample chamber filled with exhaled air. Then the beam is focused on a MCT detector D_1 to measure the intensity signal I_1 . The direct absorption of the exhaled air is calculated from I_1 and I_2 at every specific wavenumber using Lambert Beers law. We used a pulsed distributed feedback QCL from Alpes Lasers with an average output power of ~ 1 mW tuned to a spectral position at 2298 cm^{-1} by temperatures of about 10°C . By scanning the QCL a whole absorption spectrum is obtained (see Figure 3). Typically, we average up to five absorption spectra before simulating the spectra with a multi Lorentzian-fit. The areas under the Lorentzian fits correspond to the absorption in the sample and are used to calculate the ratio of $^{13}\text{CO}_2$ and $^{12}\text{CO}_2$ absorption. Typical errors for the areas of the fit are about 1%. The obtained ratio is corrected for temperature dependencies and specific properties of the measured rotation-vibrational transition [18,19]. The temperature is measured with a Pt100 sensor.

This setup allows for continuous measurement of $^{12}\text{CO}_2$ and $^{13}\text{CO}_2$ absorption spectra during respiration with online presentation of the DOB kinetics at bedside.

2.5. Operation Planning

The volumetric data before surgery is determined by CT volumetry in a four-phase contrast enhanced examination technique (LightSpeed 64[®]; GE Medical Systems, Milwaukee, IL, USA). The volumetric measurement was performed using AMIRA software (Mercury Computer Systems, Chelmsford, MA, USA) that had been validated in a prior experimental study [20]. The present study does not represent a single clinical trial. The LiMAX test had been evaluated in several clinical trials at the Charité in Berlin, which had all obtained approval of the ethics review board of the Charité medical faculty before the first patient was included. All participants gave written informed consent prior to study inclusion. In addition to the clinical trials, the test was applied in clinical routine, too. All patients gave written informed consent to perform the LiMAX test. The clinical data and DOB kinetics presented in the present manuscript were derived from a database containing all LiMAX measurements performed at the Charité. The DOB kinetics were measured with the described certificated FLIP device (Humedics GmbH, Berlin, Germany). A number of clinical trials have been published [4,21–28].

3. Results

3.1. DOB Kinetics

In Figure 5, DOB kinetics of patients with differing medical conditions are displayed. The individual data points of the DOB kinetics represent the $^{13}\text{CO}_2$ increase in the complete breath with respect to the baseline taken before ^{13}C -methacetin administration. The measured average increase of $^{13}\text{CO}_2$ in the exhaled breath within a time window of ~ 40 s is displayed by a single data point. The DOB kinetics display distinct shapes with a rise after time zero, when ^{13}C -methacetin is administered, a maximal value ranging from 1 DOB to about 50 DOB, followed by a signal decrease. The LiMAX value evaluates from the maximum of the DOB kinetics and is presented as a color coded number in $\mu\text{g/kg/h}$ next to the DOB kinetics in Figure 5. Since the signal decrease after reaching the DOB maximum is not relevant for the LiMAX value, the measurements are stopped after determination of the maximum. This procedure enables short measurement times as short as about 10 min after ^{13}C -methacetin administration (blue filled squares, and wine triangles in Figure 5). The presented rise times are in the range of 1 min–2 min for LiMAX values above $310\text{ }\mu\text{g/kg/h}$. LiMAX values of $311\text{ }\mu\text{g/kg/h}$ and higher were assigned to normal liver capacities [4,23,29]. Fast rise times can only be observed with a high data density. We displayed data points every ~ 40 s to maintain high data density and make the interpretation of the kinetics easier. In Figure 5 two pairs of DOB kinetics are plotted

for patients before and after liver surgery. The blue curves represent the DOB kinetics of a patient with metastatic colorectal cancer. Before operation the LiMAx value was determined to 649 $\mu\text{g}/\text{kg}/\text{h}$ with a fast rise of the kinetic and a maximum of about 48 DOB as displayed in Figure 5 (blue filled squares). After liver resection the DOB kinetic exhibits a lower maximum of 20 DOB reached at ~20 min after ^{13}C -methacetin administration. Nevertheless, the LiMAx value of 283 $\mu\text{g}/\text{kg}/\text{h}$ was close to the normal liver capacity. The black curves represent the DOB kinetics of another patient with cholangiocellular carcinoma before (solid black circles) and after liver resection (open black circles). The LiMAx value dropped upon liver resection from 409 $\mu\text{g}/\text{kg}/\text{h}$ to 132 $\mu\text{g}/\text{kg}/\text{h}$, directly visible by the maximum decrease from 28 DOB to 9 DOB, respectively. The rise of the DOB kinetics after liver resection (open black circles) are slowed down about five-fold, reflecting the smaller liver capacity of the reduced liver volume. The liver resections are often the exclusive curative treatment. The liver can recover completely after operation, if the remaining metabolic liver function remains above a certain threshold [21,30]. Three additional DOB kinetics are plotted in Figure 5. The green curve reflects the DOB kinetic of a patient with liver metastases after chemotherapy. Despite the toxic chemotherapy the liver capacity of this patient is in good condition again with a LiMAx value of 597 $\mu\text{g}/\text{kg}/\text{h}$. This measurement is an example for the usefulness of the LiMAx test in chemotherapy, providing information on the stressed liver.

Figure 5. DOB kinetics of five different patients (blue, green, black, wine, and red) with different liver statuses as a function of time. Administration of ^{13}C -methacetin is at time zero. A patient with mCRC (metastatic colorectal cancer) before and after operation (filled and open blue squares), patient with liver metastases and after chemotherapy (green pentagon), patient with CCC (cholangiocellular carcinoma), before and after operation (filled and open black circles), patient with heart problems (wine triangles), and a patient with CCC, cirrhosis, and alcohol abuse (red diamond). LiMAx values in $\mu\text{g}/\text{kg}/\text{h}$ for presented DOB kinetics are given as numbers next to the kinetics.

Moreover, the LiMAx test can be used for risk assessment, for example before heart operations (wine curve in Figure 5). The LiMAx value can indicate if the liver can afford the additional stress of the operation. Here, the LiMAx value shows a normal liver status with no additional risk for the operation. The red curve displays the DOB kinetic of a patient with cholangiocellular carcinoma, cirrhosis, and alcohol abuse. The DOB kinetic shows no visible rise, a maximum of 1 DOB, and a LiMAx value of 19 $\mu\text{g}/\text{kg}/\text{h}$. This curve clearly reflects liver failure.

3.2. Operation Planning

The DOB kinetics provide extremely useful information on the liver status, and the LiMAx value can be used to assess the liver capacity of a patient at bedside. As presented in Figure 5, the DOB and

LiMAx values provide direct access to the liver status before and after operation. This capability is used to plan liver operations with a reduced mortality risk [31]. A typical procedure is sketched in the following. The 3D structure of the liver is taken by CT volumetry as shown in Figure 6. Areas with liver tumors and metastases can be identified for resection. Here, the green volume of the liver is to be resected, while the yellow part, liver segment 2 and 3, should remain. The measured LiMAx value before operation is $639 \mu\text{g}/\text{kg}/\text{h}$ with a liver volume of 2.124 liters. The yellow volume has 31% of the total. The predicted LiMAx value after surgery is approximately 31% of $639 \mu\text{g}/\text{kg}/\text{h}$. This value of $198 \mu\text{g}/\text{kg}/\text{h}$ is below the normal liver capacity, but in a range in which the recovery of the liver is expected without complications [21,30,32–36]. Thus, it is possible to predict this operation is safe.

Figure 6. 3D picture of the liver before surgery measured by CT volumetry. LiMAx value before surgery was $639 \mu\text{g}/\text{kg}/\text{h}$. Liver segment 2 and 3 (yellow) are identified to remain after surgery with a calculated remnant volume of 31%.

4. Discussion and Conclusions

High precision detection of $^{13}\text{CO}_2$ and $^{12}\text{CO}_2$ in exhaled breath was reported before [10,37]. Here, we present an improved setup based on time resolved infrared absorption spectroscopy to measure an increase of the $^{13}\text{CO}_2$ concentration in the breath of humans [10]. A quantum cascade laser is used to continuously acquire absorption spectra of $^{12}\text{CO}_2$ and $^{13}\text{CO}_2$ during respiration. We stabilize the frequency position of the QCL by an automatic feedback loop. We use the complete breath of the patients and a mixing chamber to circumvent difficult breath separation procedures. Our fast detection scheme allows for averaging, and attains a high sensitivity in the clinical routine at the bedside. The very high data density follows the true increase of the DOB kinetics, that is, $^{13}\text{CO}_2$ generation and release. The additionally generated and exhaled $^{13}\text{CO}_2$ can be considered to come solely from ^{13}C -methacetin metabolization in the liver cells. Thus, the fast increase of the DOB kinetics directly reflects the liver metabolization of ^{13}C -methacetin by cytochrome P450 1A2. The precise detection of the DOB kinetics by the described FLIP device allows for accurate determination of the personalized LiMAx value. The LiMAx value is successfully used in clinical routine to reduce the mortality rate upon liver resections by more than 70% [8,9]. A variety of other application areas have been reported [26,29,38–40]. The combination of the LiMAx test with the QCL-based FLIP device presented here will revolutionize liver therapy and medical fields in which the liver plays a vital role.

Acknowledgments: We thank the Bundesministerium für Wirtschaft und Energie (Exist-Gründerstipendium 2008/0066-V and 2008/0066) for financial support.

Author Contributions: T.R. developed the prototype, programming, performed the fundamental experiments, and identified further challenges of the method. T.v.H. improved the programming, data fitting, and developed the electronics and data acquisition. A.H. assembled the next generation FLIP and performed calibration of the setup. J.L. performed the experiments with FLIP devices in the hospital at bedside, and contributed to the usability of the FLIP. M.S. invented the LiMAx test, worked out application areas of the LiMAx test and contributed significantly to specifications and usability of the FLIP. K.H. designed, planned, developed and optimized the FLIP in all stages. He analyzed data and optimized the analysis procedure and the complete device. K.H. wrote the paper.

Conflicts of Interest: The authors M.S. and K.H. are shareholders of Humedics GmbH. Humedics GmbH market the FLIP devices and the LiMAx test. A.H. is employed at Humedics GmbH. The authors declare that Humedics GmbH had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Abbreviations

The following abbreviations are used in this manuscript:

DOB	Delta over baseline
LiMAx	Liver maximal capacity
QCL	Quantum cascade laser
MCT	Mercury Cadmium Telluride

References

1. Beauchamp, J. Inhaled today, not gone tomorrow: Pharmacokinetics and environmental exposure of volatiles in exhaled breath. *J. Breath Res.* **2011**, *5*, 037103. [[CrossRef](#)] [[PubMed](#)]
2. Gisbert, J.P.; Pajares, J.M. Review article: ¹³C-urea breath test in the diagnosis of helicobacter pylori infection—A critical review. *Aliment. Pharmacol. Ther.* **2004**, *20*, 1001–1017. [[CrossRef](#)] [[PubMed](#)]
3. Haisch, M.; Hering, P.; Fuss, W.; Fabinski, W. A sensitive isotope selective nondispersive infrared spectrometer for ¹³CO₂ and ¹²CO₂ concentration measurements in breath samples. *Isot. Environ. Health Stud.* **1994**, *30*, 247–251. [[CrossRef](#)]
4. Stockmann, M.; Lock, J.F.; Riecke, B.; Heyne, K.; Martus, P.; Fricke, M.; Lehmann, S.; Niehues, S.M.; Schwabe, M.; Lemke, A.J.; *et al.* Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. *Ann. Surg.* **2009**, *250*, 119–125. [[CrossRef](#)] [[PubMed](#)]
5. Schoeller, D.A.; Luke, A.H. Rapid ¹⁸O analysis of CO₂ samples by continuous-flow isotope ratio mass spectrometry. *J. Mass Spectrom.* **1997**, *32*, 1332–1336. [[CrossRef](#)]
6. Braden, B.; Haisch, M.; Duan, L.; Lembcke, B.; Caspary, W.; Hering, P. Clinically feasible stable isotope technique at a reasonable price: Analysis of ¹³CO₂/¹²CO₂-abundance in breath samples with a new isotope selective-nondispersive infrared spectrometer. *Z. Gastroenterol.* **1994**, *32*, 675–678. [[PubMed](#)]
7. Haycock, G.B.; Schwartz, G.J.; Wisotsky, D.H. Geometric method for measuring body surface area: A height-weight formula validated in infants, children, and adults. *J. Pediatr.* **1978**, *93*, 62–66. [[CrossRef](#)]
8. Stockmann, M.; Lock, J.F.; Malinowski, M.; Niehues, S.M.; Seehofer, D.; Neuhaus, P. The limax test: A new liver function test for predicting postoperative outcome in liver surgery. *HPB* **2010**, *12*, 139–146. [[CrossRef](#)] [[PubMed](#)]
9. Jara, M.; Reese, T.; Malinowski, M.; Valle, E.; Seehofer, D.; Puhl, G.; Neuhaus, P.; Pratschke, J.; Stockmann, M. Reductions in post-hepatectomy liver failure and related mortality after implementation of the limax algorithm in preoperative work-up: A single centre analysis of 1170 hepatectomies of one or more segments. *HPB* **2015**, *17*, 651–658. [[CrossRef](#)] [[PubMed](#)]
10. Rubin, T.; von Haimberger, T.; Helmke, A.; Heyne, K. Quantitative determination of metabolization dynamics by a real-time ¹³CO₂ breath test. *J. Breath Res.* **2011**, *5*, 027102. [[CrossRef](#)] [[PubMed](#)]
11. Rubin, T. Konzeption und Entwicklung eines Infrarot-Spektrometers zur Bestimmung der Konzentration von ¹³CO₂ und ¹²CO₂ im Gasfluss. Available online: http://edocs.fu-berlin.de/docs/receive/FUDOCSDocument_000000024491 (accessed on 13 May 2016).
12. Lourenco, C.; Turner, C. Breath analysis in disease diagnosis: Methodological considerations and applications. *Metabolites* **2014**, *4*, 465–498. [[CrossRef](#)] [[PubMed](#)]
13. Rubin, T.; Heyne, K. Apparatus for Infrared Absorption Spectroscopy with Pre-Chamber for Homogenising A Test Gas. De. Patent EP 2626128 A1 20130814, 2009.

14. Nelson, D.D.; McManus, B.; Urbanski, S.; Herndon, S.; Zahniser, M.S. High precision measurements of atmospheric nitrous oxide and methane using thermoelectrically cooled mid-infrared quantum cascade lasers and detectors. *Spectrochim. Acta A Mol. Biomol. Spectrosc.* **2004**, *60*, 3325–3335. [[CrossRef](#)] [[PubMed](#)]
15. McManus, J.B.; Zahniser, M.S.; Nelson, D.D.; Williams, L.R.; Kolb, C.E. Infrared laser spectrometer with balanced absorption for measurement of isotopic ratios of carbon gases. *Spectrochim. Acta A Mol. Biomol. Spectrosc.* **2002**, *58*, 2465–2479. [[CrossRef](#)]
16. Wysocki, G.; McCurdy, M.; So, S.; Weidmann, D.; Roller, C.; Curl, R.F.; Tittel, F.K. Pulsed quantum-cascade laser-based sensor for trace-gas detection of carbonyl sulfide. *Appl. Opt.* **2004**, *43*, 6040–6046. [[CrossRef](#)] [[PubMed](#)]
17. Nelson, D.; Shorter, J.; McManus, J.; Zahniser, M. Sub-part-per-billion detection of nitric oxide in air using a thermoelectrically cooled mid-infrared quantum cascade laser spectrometer. *Appl. Phys. B* **2002**, *75*, 343–350. [[CrossRef](#)]
18. Rothman, L.S.; Gordon, I.E.; Barbe, A.; Benner, D.C.; Bernath, P.F.; Birk, M.; Boudon, V.; Brown, L.R.; Campargue, A.; Champion, J.-P. The hitran 2008 molecular spectroscopic database. *J. Quant. Spectrosc. Radiat. Transf.* **2009**, *110*, 533–572. [[CrossRef](#)]
19. Herzberg, G. *Infrared and Raman Spectra of Polyatomic Molecules*; D. Van Nostrand Company: New York, NY, USA, 1945.
20. Niehues, S.M.; Unger, J.K.; Malinowski, M.; Neymeyer, J.; Hamm, B.; Stockmann, M. Liver volume measurement: Reason of the difference between *in vivo* ct-volumetry and intraoperative *ex vivo* determination and how to cope it. *Eur J. Med. Res.* **2010**, *15*, 345–350. [[CrossRef](#)] [[PubMed](#)]
21. Lock, J.F.; Schwabauer, E.; Martus, P.; Videv, N.; Pratschke, J.; Malinowski, M.; Neuhaus, P.; Stockmann, M. Early diagnosis of primary nonfunction and indication for reoperation after liver transplantation. *Liver Transplant.* **2010**, *16*, 172–180. [[CrossRef](#)] [[PubMed](#)]
22. Kaffarnik, M.F.; Lock, J.F.; Vetter, H.; Ahmadi, N.; Lojewski, C.; Malinowski, M.; Neuhaus, P.; Stockmann, M. Early diagnosis of sepsis-related hepatic dysfunction and its prognostic impact on survival: A prospective study with the limax test. *Crit. Care* **2013**, *17*, R259. [[CrossRef](#)] [[PubMed](#)]
23. Lock, J.F.; Kotobi, A.N.; Malinowski, M.; Schulz, A.; Jara, M.; Neuhaus, P.; Stockmann, M. Predicting the prognosis in acute liver failure: Results from a retrospective pilot study using the limax test. *Ann. Hepatol.* **2013**, *12*, 556–562. [[PubMed](#)]
24. Brinkhaus, G.; Lock, J.F.; Malinowski, M.; Denecke, T.; Neuhaus, P.; Hamm, B.; Gebauer, B.; Stockmann, M. Ct-guided high-dose-rate brachytherapy of liver tumours does not impair hepatic function and shows high overall safety and favourable survival rates. *Ann. Surg. Oncol.* **2014**, *21*, 4284–4292. [[CrossRef](#)] [[PubMed](#)]
25. Hoppe, S.; von Loeffelholz, C.; Lock, J.F.; Doecke, S.; Sinn, B.V.; Rieger, A.; Malinowski, M.; Pfeiffer, A.F.; Neuhaus, P.; Stockmann, M. Nonalcoholic steatohepatitis and liver steatosis modify partial hepatectomy recovery. *J. Investig. Surg.* **2015**, *28*, 24–31. [[CrossRef](#)] [[PubMed](#)]
26. Jara, M.; Malinowski, M.; Lüttgert, K.; Schott, E.; Neuhaus, P.; Stockmann, M. Prognostic value of enzymatic liver function for the estimation of short-term survival of liver transplant candidates: A prospective study with the limax test. *Transpl. Int.* **2015**, *28*, 52–58. [[CrossRef](#)] [[PubMed](#)]
27. Malinowski, M.; Stary, V.; Lock, J.F.; Schulz, A.; Jara, M.; Seehofer, D.; Gebauer, B.; Denecke, T.; Geisel, D.; Neuhaus, P.; *et al.* Factors influencing hypertrophy of the left lateral liver lobe after portal vein embolization. *Langenbecks Arch. Surg.* **2015**, *400*, 237–246. [[CrossRef](#)] [[PubMed](#)]
28. Jara, M.; Bednarsch, J.; Malinowski, M.; Pratschke, J.; Stockmann, M. Effects of oxaliplatin-based chemotherapy on liver function—an analysis of impact and functional recovery using the limax test. *Langenbecks Arch. Surg.* **2016**, *401*, 33–41. [[CrossRef](#)] [[PubMed](#)]
29. Jara, M.; Bednarsch, J.; Valle, E.; Lock, J.F.; Malinowski, M.; Schulz, A.; Seehofer, D.; Jung, T.; Stockmann, M. Reliable assessment of liver function using limax. *J. Surg. Res.* **2015**, *193*, 184–189. [[CrossRef](#)] [[PubMed](#)]
30. Stockmann, M.; Lock, J.F.; Malinowski, M.; Seehofer, D.; Puhl, G.; Pratschke, J.; Neuhaus, P. How to define initial poor graft function after liver transplantation?—A new functional definition by the limax test. *Transpl. Int.* **2010**, *23*, 1023–1032. [[CrossRef](#)] [[PubMed](#)]
31. Kaffarnik, M.F.; Lock, J.F.; Seehofer, D.; Stockmann, M.; Neuhaus, P. Leberresektionen—Was ist perioperativ zu beachten? *Viszeralmedizin* **2011**, *27*, 65–73. [[CrossRef](#)]
32. Fan, S.-T.; Lo, C.-M.; Liu, C.-L.; Yong, B.-H.; Chan, J.K.-F.; Ng, I.O.-L. Safety of donors in live donor liver transplantation using right lobe grafts. *Arch. Surg.* **2000**, *135*, 336–340. [[CrossRef](#)] [[PubMed](#)]

33. Ferrero, A.; Viganò, L.; Polastri, R.; Muratore, A.; Eminefendic, H.; Regge, D.; Capussotti, L. Postoperative liver dysfunction and future remnant liver: Where is the limit? *World J. Surg.* **2007**, *31*, 1643–1651. [[CrossRef](#)] [[PubMed](#)]
34. Guglielmi, A.; Ruzzenente, A.; Conci, S.; Valdegamberi, A.; Iacono, C. How much remnant is enough in liver resection? *Dig. Surg.* **2012**, *29*, 6–17. [[CrossRef](#)] [[PubMed](#)]
35. Truant, S.; Oberlin, O.; Sergent, G.; Lebuffe, G.; Gambiez, L.; Ernst, O.; Pruvot, F.-R. Remnant liver volume to body weight ratio $\geq 0.5\%$: A new cut-off to estimate postoperative risks after extended resection in noncirrhotic liver. *J. Am. Coll. Surg.* **2007**, *204*, 22–33. [[CrossRef](#)] [[PubMed](#)]
36. Van Den Broek, M.A.; Olde Damink, S.W.; Dejong, C.H.; Lang, H.; Malagó, M.; Jalan, R.; Saner, F.H. Liver failure after partial hepatic resection: Definition, pathophysiology, risk factors and treatment. *Liver Int.* **2008**, *28*, 767–780. [[CrossRef](#)] [[PubMed](#)]
37. Kasyutich, V.L.; Martin, P.A. (CO₂)-C-13/(CO₂)-C-12 isotopic ratio measurements with a continuous-wave quantum cascade laser in exhaled breath. *Infrared Phys. Technol.* **2012**, *55*, 60–66. [[CrossRef](#)]
38. Lock, J.F.; Malinowski, M.; Seehofer, D.; Hoppe, S.; Röhl, R.I.; Niehues, S.M.; Neuhaus, P.; Stockmann, M. Function and volume recovery after partial hepatectomy: Influence of preoperative liver function, residual liver volume, and obesity. *Langenbecks Arch. Surg.* **2012**, *397*, 1297–1304. [[CrossRef](#)] [[PubMed](#)]
39. Malinowski, M.; Jara, M.; Lüttgert, K.; Orr, J.; Lock, J.F.; Schott, E.; Stockmann, M. Enzymatic liver function capacity correlates with disease severity of patients with liver cirrhosis: A study with the limax test. *Dig. Dis. Sci.* **2014**, *59*, 2983–2991. [[CrossRef](#)] [[PubMed](#)]
40. Alizai, P.H.; Wendl, J.; Roeth, A.A.; Klink, C.D.; Luedde, T.; Steinhoff, I.; Neumann, U.P.; Schmeding, M.; Ulmer, F. Functional liver recovery after bariatric surgery—A prospective cohort study with the limax test. *Obes. Surg.* **2015**, *25*, 2047–2053. [[CrossRef](#)] [[PubMed](#)]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<http://creativecommons.org/licenses/by/4.0/>).